FRIDAY, June 18 (HealthDay News) -- A U.S. Food and Drug
Administration advisory panel on Friday unanimously agreed that a
pill dubbed by some as a "female Viagra" did not show strong enough
benefits to warrant approval.
Called flibanserin, the drug was aimed at premenopausal women
with a diminished sex drive. It is related to the antidepressant
family and affects serotonin and other chemicals in the brain. Drug
maker Boehringer Ingelheim has been seeking FDA approval of the
According to the
Associated Press, the FDA advisers voted 11-0 that benefits linked to the pill did not outweigh side effects such as fainting spells, fatigue and depression.
While the agency isn't compelled to follow the recommendations
of its advisory panels, it typically does so.
Earlier this week, the FDA released a review of two studies that
found the drug didn't have much impact on a woman's libido but did
seem to slightly boost sexual satisfaction, according to published
The drug, with the proposed brand name Girosa, is designed to be
taken in 100-milligram pills once a day at bedtime, according to
Since the extraordinary success of Viagra for men, which hit the
market a decade ago, pharmaceutical companies have repeatedly tried
to find a comparable drug treatment for women. But none of those
treatments has resulted in a significant benefit.
To learn more about women's sexual health, visit the
Society for the Study of Women's Sexual Health.